# Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

> **NCT05558956** · EARLY_PHASE1 · UNKNOWN · sponsor: **BAMF Health** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** illuccix 68Ga-PSMA-11 Total Body PET-CT

## Key facts

- **NCT ID:** NCT05558956
- **Lead sponsor:** BAMF Health
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05558956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05558956, "Total Body PET-CT Imaging of Prostate Cancer Using Illuccix". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05558956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*